Elekta Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Elekta wird ein jährliches Gewinn- und Umsatzwachstum von 17.9% bzw. 6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.5% betragen.

Wichtige Informationen

17.9%

Wachstumsrate der Gewinne

17.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	6.0%
Zukünftige Eigenkapitalrendite	17.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:EKTA.F - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
4/30/2027	21,219	2,188	1,799	3,594	10
4/30/2026	19,944	1,923	1,571	3,296	13
4/30/2025	18,840	1,542	905	2,569	13
7/31/2024	18,116	1,134	824	2,519	N/A
4/30/2024	18,119	1,302	817	2,461	N/A
1/31/2024	18,221	1,433	1,518	3,135	N/A
10/31/2023	18,021	1,344	724	2,289	N/A
7/31/2023	17,370	1,121	96	1,611	N/A
4/30/2023	16,869	943	400	1,964	N/A
1/31/2023	15,984	813	-551	1,013	N/A
10/31/2022	15,249	826	-201	1,361	N/A
7/31/2022	14,866	1,087	200	1,741	N/A
4/30/2022	14,548	1,154	450	1,858	N/A
1/31/2022	13,976	1,079	648	1,933	N/A
10/31/2021	13,955	1,172	958	2,049	N/A
7/31/2021	13,791	1,165	1,302	2,259	N/A
4/30/2021	13,763	1,254	1,706	2,551	N/A
1/31/2021	14,104	1,321	1,739	2,680	N/A
10/31/2020	14,179	1,307	1,088	1,970	N/A
7/31/2020	14,354	1,153	1,044	1,854	N/A
4/30/2020	14,601	1,084	252	1,014	N/A
1/31/2020	14,680	1,212	623	1,318	N/A
10/31/2019	14,343	1,115	619	1,281	N/A
7/31/2019	13,964	1,179	741	1,373	N/A
4/30/2019	13,555	1,198	962	1,621	N/A
1/31/2019	12,877	1,164	554	1,307	N/A
10/31/2018	12,315	1,295	1,241	2,056	N/A
7/31/2018	11,888	1,315	1,092	1,947	N/A
4/30/2018	11,573	1,348	N/A	2,404	N/A
1/31/2018	11,879	939	N/A	2,393	N/A
10/31/2017	11,795	639	N/A	2,095	N/A
7/31/2017	11,326	389	N/A	2,034	N/A
4/30/2017	10,704	125	N/A	1,819	N/A
1/31/2017	10,596	108	N/A	1,442	N/A
10/31/2016	10,470	70	N/A	1,375	N/A
7/31/2016	10,864	203	N/A	1,380	N/A
4/30/2016	11,221	137	N/A	1,170	N/A
1/31/2016	11,469	402	N/A	1,989	N/A
10/31/2015	11,474	548	N/A	1,862	N/A
7/31/2015	11,213	558	N/A	1,952	N/A
4/30/2015	10,839	552	N/A	1,823	N/A
1/31/2015	10,938	1,029	N/A	1,389	N/A
10/31/2014	10,771	1,026	N/A	1,342	N/A
7/31/2014	10,647	1,017	N/A	1,188	N/A
4/30/2014	10,694	1,148	N/A	1,275	N/A
1/31/2014	10,471	1,173	N/A	1,219	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EKTA.FDas prognostizierte Gewinnwachstum (17.9% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: EKTA.FDie Erträge des Unternehmens (17.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.2% pro Jahr).

Hohe Wachstumserträge: EKTA.FDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: EKTA.FDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: EKTA.FDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EKTA.FDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.5%).

Elekta Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Elekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025

Elekta Not Provides Earnings Guidance for the Year of 2021

Recent updates

Caroline Leksell Cooke Steps Down from Elekta AB's Board of Directors

Elekta AB Submits Elekta Evo to U.S. FDA for Premarket Approval

Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, Respectively

Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025

Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025

Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the Board

Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024

Elekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024

Elekta AB (publ) Announces Composition of Nomination Committee

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

Elekta AB (publ), Annual General Meeting, Sep 05, 2024

Elekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, Respectively

Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)

Elekta AB (publ) to Report Q3, 2024 Results on Feb 09, 2024

Elekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025

Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONE

Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.

Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.

First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-Linac

Elekta AB (publ), Annual General Meeting, Aug 24, 2023

Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain Disease

Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) Clearance

Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual Meeting

Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)

Elekta AB (publ) Elects Kelly Londy as a Director

Elekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023

Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22

Elekta Launches New Radiosurgery System: Elekta Esprit

Elekta AB (publ) to Report Fiscal Year 2022 Final Results on Jul 08, 2022

Elekta AB (publ), Annual General Meeting, Aug 25, 2022

Elekta AB (publ) (OM:EKTA B) acquired Özyürek Mümessillik ve Dis Ticaret A.S.

Elekta AB (Publ)'s Elekta Harmony Radiation Therapy System Receives U.S. FDA 510(K) Clearance

Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021

Elekta AB (Publ) Approves Extra Dividend, Payable on 23 April 2021

Elekta AB (publ) Proposes Extra Dividend, Payable on 23 April 2021

Elekta and IBA Strengthen Partnership to Help Cancer Centers Integrate Proton Therapy

Elekta Not Provides Earnings Guidance for the Year of 2021

First Cancer Centers Begin Using Initial Release of Elekta's MOSAIQ 3 Series

Elekta AB (publ) (OM:EKTA B) signed an agreement to acquire Oncology division from Horizon for Medical Appliances.

Elekta's ProKnow to Help Standardize Radiotherapy for Veterans

An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million.

Elekta Appoints Gustaf Salford as CEO

Elekta Introduces Elekta Studio with Its Launch of the ImagingRing

Elekta Early Out in Securing MDR Certificates for Its Linac Portfolio

Elekta AB (publ) to Report Fiscal Year 2021 Results on May 27, 2021

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken